The Importance of Pleading Actual Harm in Trade Secret Misappropriation Cases
In an April 25, 2012 ruling [pdf] a Middle District of North Carolina court clearly illustrated the importance of pleading actual harm in an unfair competition case. By dismissing parts of a dispute between River’s Edge Pharmaceuticals, a discount pharmaceutical product distributor, and Gorbec Pharmaceutical Services, Inc., a pharmaceutical manufacturer, the court ruled that speculation about potential harm is not enough to sustain a litigant’s burden.
In 2003, River’s Edge first developed products through an FDA-sanctioned program. River’s Edge sought help from Gorbec in 2007 to manufacture and test generic drugs under an Abbreviated New Drug Application (ANDA) process. The parties contemplated preparing a written contract to memorialize their agreement, but never completed one. River’s Edge submitted purchase orders to Gorbec to manufacture drugs to River’s Edge’s specifications.
In 2010, the relationship soured. River’s Edge claimed Gorbec executives boasted of having the “know-how, intellectual property, and regulatory approvals,” threatened to stop work, and made plans to compete. Gorbec claimed River’s Edge failed to pay Gorbec in full, and hid a warning letter from the FDA asking River’s Edge to cease sales. Both sued. River’s Edge’s complaint alleged breaches of contract and fiduciary duty, fraud, promissory estoppel, unjust enrichment, conversion, and misappropriation of trade secrets; and sought declaratory relief. Gorbec’s counterclaim was almost a mirror image, alleging breach of contract, unjust enrichment, negligent misrepresentation, fraud, and deceptive trade practices.
By
By
By
By 